{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T01:45:31Z","timestamp":1784771131990,"version":"3.55.0"},"reference-count":44,"publisher":"Elsevier BV","issue":"6-7","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T00:00:00Z","timestamp":1725926400000},"content-version":"am","delay-in-days":375,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer\/Radioth\u00e9rapie"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.canrad.2023.06.021","type":"journal-article","created":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T12:15:38Z","timestamp":1690460138000},"page":"659-665","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Stereotactic radiotherapy for ultracentral lung tumours"],"prefix":"10.1016","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2631-0029","authenticated-orcid":false,"given":"V.","family":"Bourbonne","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Thureau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Pradier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Antoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Lucia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canrad.2023.06.021_bib0225","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/S1470-2045(15)70168-3","article-title":"Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials","volume":"16","author":"Chang","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.canrad.2023.06.021_bib0230","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.lungcan.2015.01.005","article-title":"Comparison of clinical outcome of stage I non-small cell lung cancer treated surgically or with stereotactic radiotherapy: results from propensity score analysis","volume":"87","author":"Mokhles","year":"2015","journal-title":"Lung Cancer"},{"key":"10.1016\/j.canrad.2023.06.021_bib0235","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1001\/jamasurg.2014.556","article-title":"Lobectomy, sublobar resection, and stereotactic ablative radiotherapy for early-stage non-small cell lung cancers in the elderly","volume":"149","author":"Shirvani","year":"2014","journal-title":"JAMA Surg"},{"key":"10.1016\/j.canrad.2023.06.021_bib0240","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1093\/annonc\/mdt026","article-title":"Stage I-II non-small-cell lung cancer treated using either stereotactic ablative radiotherapy (SABR) or lobectomy by video-assisted thoracoscopic surgery (VATS): outcomes of a propensity score-matched analysis","volume":"24","author":"Verstegen","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.canrad.2023.06.021_bib0245","doi-asserted-by":"crossref","first-page":"S94","DOI":"10.1097\/JTO.0b013e318074de34","article-title":"Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: updated results of 257 patients in a Japanese multi-institutional study","volume":"2","author":"Onishi","year":"2007","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.canrad.2023.06.021_bib0250","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.canrad.2021.11.001","article-title":"Organs at risk radiation dose constraints","volume":"26","author":"No\u00ebl","year":"2022","journal-title":"Cancer Radiother"},{"key":"10.1016\/j.canrad.2023.06.021_bib0255","doi-asserted-by":"crossref","first-page":"4833","DOI":"10.1200\/JCO.2006.07.5937","article-title":"Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer","volume":"24","author":"Timmerman","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2023.06.021_bib0260","doi-asserted-by":"crossref","first-page":"1600764","DOI":"10.1183\/13993003.00764-2016","article-title":"Management of stage I and II nonsmall cell lung cancer","volume":"49","author":"McDonald","year":"2017","journal-title":"Eur Respir J"},{"key":"10.1016\/j.canrad.2023.06.021_bib0265","doi-asserted-by":"crossref","first-page":"S872","DOI":"10.21037\/jtd.2016.06.48","article-title":"Bronchial and arterial sleeve resection for centrally-located lung cancers","volume":"8","author":"Maurizi","year":"2016","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.canrad.2023.06.021_bib0270","doi-asserted-by":"crossref","first-page":"S882","DOI":"10.21037\/jtd.2016.08.47","article-title":"Carinal resection and sleeve pneumonectomy","volume":"8","author":"Weder","year":"2016","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.canrad.2023.06.021_bib0275","doi-asserted-by":"crossref","first-page":"497","DOI":"10.6004\/jnccn.2022.0025","article-title":"Non-small cell lung cancer, version 3.2022, NCCN clinical practice guidelines in oncology","volume":"20","author":"Ettinger","year":"2022","journal-title":"J Natl Compr Cancer Netw"},{"key":"10.1016\/j.canrad.2023.06.021_bib0280","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1097\/JTO.0b013e31824165d7","article-title":"Is there a lower limit of pretreatment pulmonary function for safe and effective stereotactic body radiotherapy for early-stage non-small cell lung cancer?","volume":"7","author":"Guckenberger","year":"2012","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.canrad.2023.06.021_bib0285","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.canrad.2021.08.011","article-title":"Lung metastases radiation therapy","volume":"26","author":"L\u00e9vy","year":"2022","journal-title":"Cancer Radiother"},{"key":"10.1016\/j.canrad.2023.06.021_bib0290","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.ijrobp.2009.09.042","article-title":"American Society for Therapeutic Radiology and Oncology (ASTRO) and American College of Radiology (ACR) practice guideline for the performance of stereotactic body radiation therapy","volume":"76","author":"Potters","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2023.06.021_bib0295","doi-asserted-by":"crossref","first-page":"4078","DOI":"10.1118\/1.3438081","article-title":"Stereotactic body radiation therapy: the report of AAPM Task Group 101","volume":"37","author":"Benedict","year":"2010","journal-title":"Med Phys"},{"key":"10.1016\/j.canrad.2023.06.021_bib0300","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.canrad.2021.09.006","article-title":"Respiratory motion management for external radiotherapy treatment","volume":"26","author":"Darr\u00e9on","year":"2022","journal-title":"Cancer Radiother"},{"key":"10.1016\/j.canrad.2023.06.021_bib0305","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.radonc.2022.04.005","article-title":"Thorough design and pre-trial quality assurance (QA) decrease dosimetric impact of delineation and dose planning variability in the STRICTLUNG and STARLUNG trials for stereotactic body radiotherapy (SBRT) of central and ultra-central lung tumours","volume":"171","author":"Hoffmann","year":"2022","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2023.06.021_bib0310","doi-asserted-by":"crossref","unstructured":"DeLuca P., Jones D., Gahbauer R., Whitmore G. The international commission on radiation units and measurements J ICRU 2010;10. [NP.2-NP].","DOI":"10.1093\/jicru\/ndq001"},{"key":"10.1016\/j.canrad.2023.06.021_bib0315","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13014-020-01491-w","article-title":"Outcomes of stereotactic body radiotherapy 60\u00a0Gy in 8 fractions when prioritizing organs at risk for central and ultracentral lung tumors","volume":"15","author":"Zhao","year":"2020","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.canrad.2023.06.021_bib0320","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.cllc.2020.11.003","article-title":"Safety and efficacy of stereotactic body radiotherapy in ultracentral lung tumors using a risk-optimized fractionation scheme","volume":"22","author":"Regnery","year":"2021","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.canrad.2023.06.021_bib0325","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1080\/0284186X.2021.1942545","article-title":"Ultra-central lung tumors: safety and efficacy of protracted stereotactic body radiotherapy","volume":"60","author":"Lodeweges","year":"2021","journal-title":"Acta Oncol"},{"key":"10.1016\/j.canrad.2023.06.021_bib0330","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.jtho.2016.03.008","article-title":"Outcomes of hypofractionated high-dose radiotherapy in poor-risk patients with \u201cultracentral\u201d non-small cell lung cancer","volume":"11","author":"Tekatli","year":"2016","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.canrad.2023.06.021_bib0335","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.clon.2021.05.005","article-title":"Late Toxicity and Long-Term Local Control in Patients With Ultra-Central Lung Tumours Treated by Intensity-Modulated Radiotherapy-Based Stereotactic Ablative Body Radiotherapy With Homogenous Dose Prescription","volume":"33","author":"Mihai","year":"2021","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.canrad.2023.06.021_bib0340","doi-asserted-by":"crossref","first-page":"868844","DOI":"10.3389\/fonc.2022.868844","article-title":"Safety and efficacy of stereotactic ablative radiotherapy for ultra-central lung cancer","volume":"12","author":"Wang","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.canrad.2023.06.021_bib0345","doi-asserted-by":"crossref","first-page":"5908","DOI":"10.3390\/cancers14235908","article-title":"Survival and prognostic factors of ultra-central tumors treated with stereotactic body radiotherapy","volume":"14","author":"Salvestrini","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.canrad.2023.06.021_bib0350","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.radonc.2021.03.001","article-title":"Ablative radiotherapy for ultracentral lung cancers: dosimetric, geometric, and volumetric predictors of outcomes and toxicity","volume":"158","author":"Breen","year":"2021","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2023.06.021_bib0355","doi-asserted-by":"crossref","first-page":"3463","DOI":"10.3390\/cancers13143463","article-title":"Exceeding radiation dose to volume parameters for the proximal airways with stereotactic body radiation therapy is more likely for ultracentral lung tumors and associated with worse outcome","volume":"13","author":"Farrugia","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.canrad.2023.06.021_bib0360","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.lungcan.2020.07.009","article-title":"Analysis of pneumonitis and esophageal injury after stereotactic body radiation therapy for ultra-central lung tumors","volume":"147","author":"Wang","year":"2020","journal-title":"Lung Cancer"},{"key":"10.1016\/j.canrad.2023.06.021_bib0365","doi-asserted-by":"crossref","first-page":"20210533","DOI":"10.1259\/bjr.20210533","article-title":"Toxicity and efficacy of stereotactic body radiotherapy for ultra-central lung tumours: a single institution real life experience","volume":"95","author":"Guillaume","year":"2022","journal-title":"Br J Radiol"},{"key":"10.1016\/j.canrad.2023.06.021_bib0370","doi-asserted-by":"crossref","first-page":"3553","DOI":"10.1111\/cas.14185","article-title":"Risk-adapted stereotactic body radiation therapy for central and ultra-central early-stage inoperable non-small cell lung cancer","volume":"110","author":"Meng","year":"2019","journal-title":"Cancer Sci"},{"key":"10.1016\/j.canrad.2023.06.021_bib0375","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.radonc.2018.07.001","article-title":"The safety and effectiveness of stereotactic body radiotherapy for central versus ultracentral lung tumors","volume":"129","author":"Chang","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2023.06.021_bib0380","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1007\/s00066-020-01687-9","article-title":"Dose coverage impacts local control in ultra-central lung oligometastases treated with stereotactic radiotherapy","volume":"197","author":"Loi","year":"2021","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.canrad.2023.06.021_bib0385","doi-asserted-by":"crossref","first-page":"e173","DOI":"10.1016\/j.clon.2022.11.013","article-title":"Accelerated hypofractionated radiotherapy for centrally located lung tumours not suitable for stereotactic body radiotherapy or chemoradiotherapy","volume":"35","author":"Zeng","year":"2023","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.canrad.2023.06.021_bib0390","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.jtho.2021.03.019","article-title":"The HILUS-trial-a prospective Nordic multicenter phase 2 study of ultracentral lung tumors treated with stereotactic body radiotherapy","volume":"16","author":"Lindberg","year":"2021","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.canrad.2023.06.021_bib0395","series-title":"Late toxicity following stereotactic radiotherapy (SABR) for central and ultracentral lung tumors","author":"Tekatli","year":"2023"},{"key":"10.1016\/j.canrad.2023.06.021_bib0400","series-title":"Lungtech EORTC 22113-08113 prospective multicenter trial: SBRT for central lung tumors","author":"Nestle","year":"2023"},{"key":"10.1016\/j.canrad.2023.06.021_bib0405","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1016\/j.jtho.2018.07.017","article-title":"Stereotactic body radiation therapy for central early-stage NSCLC: results of a prospective phase I\/II trial","volume":"13","author":"Roach","year":"2018","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.canrad.2023.06.021_bib0410","doi-asserted-by":"crossref","first-page":"e529","DOI":"10.1016\/j.cllc.2018.04.001","article-title":"SUNSET: stereotactic radiation for ultracentral non-small-cell lung cancer-A safety and efficacy trial","volume":"19","author":"Giuliani","year":"2018","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.canrad.2023.06.021_bib0415","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.2217\/fon-2019-0061","article-title":"Retrospective comparison of stereotactic body radiotherapy versus intensity-modulated radiotherapy for stage III ultra-central squamous non-small-cell lung cancer","volume":"15","author":"Cong","year":"2019","journal-title":"Future Oncol"},{"key":"10.1016\/j.canrad.2023.06.021_bib0420","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1111\/1759-7714.13105","article-title":"Outcomes and toxicity of stereotactic body radiation therapy for advanced stage ultra-central non-small cell lung cancer","volume":"10","author":"Cong","year":"2019","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.canrad.2023.06.021_bib0425","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1186\/s13014-017-0897-6","article-title":"Five-fraction SBRT for ultra-central NSCLC in-field recurrences following high-dose conventional radiation","volume":"12","author":"Repka","year":"2017","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.canrad.2023.06.021_bib0430","doi-asserted-by":"crossref","first-page":"e301","DOI":"10.1016\/j.cllc.2020.05.010","article-title":"Ultra-central thoracic re-irradiation using 10-fraction stereotactic body radiotherapy for recurrent non-small-cell lung cancer tumors: preliminary toxicity and efficacy outcomes","volume":"22","author":"Sood","year":"2021","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.canrad.2023.06.021_bib0435","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s13014-022-02070-x","article-title":"Magnetic resonance guided adaptive stereotactic body radiotherapy for lung tumors in ultracentral location: the MAGELLAN trial (ARO 2021-3)","volume":"17","author":"Regnery","year":"2022","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.canrad.2023.06.021_bib0440","first-page":"100488","article-title":"Magnetic resonance-guided stereotactic body radiation therapy\/hypofractionated radiation therapy for metastatic and primary central and ultracentral lung lesions","volume":"4","author":"Sandoval","year":"2023","journal-title":"JTO Clin Res Rep"}],"container-title":["Cancer\/Radioth\u00e9rapie"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1278321823001300?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1278321823001300?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T12:38:17Z","timestamp":1761136697000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1278321823001300"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":44,"journal-issue":{"issue":"6-7","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S1278321823001300"],"URL":"https:\/\/doi.org\/10.1016\/j.canrad.2023.06.021","relation":{},"ISSN":["1278-3218"],"issn-type":[{"value":"1278-3218","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Stereotactic radiotherapy for ultracentral lung tumours","name":"articletitle","label":"Article Title"},{"value":"Cancer\/Radioth\u00e9rapie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canrad.2023.06.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Masson SAS on behalf of Soci\u00e9t\u00e9 fran\u00e7aise de radioth\u00e9rapie oncologique (SFRO).","name":"copyright","label":"Copyright"}]}}